Protein C, protein S and von Willebrand factor levels correlate with bleeding symptoms: A population-based study

Haemophilia

Volumn 18, Issue 3, 2012, Pages 457-462

  Rojnuckarin, P ^a   Uaprasert, N ^a   Akkawat, B ^a   Settapiboon, R ^a   Nanakorn, T ^a   Intragumtornchai, T ^a  

^a CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

Bleeding scores; Protein C; Protein S; Von Willebrand factor

Indexed keywords

PROTEIN C; PROTEIN S; VON WILLEBRAND FACTOR;

ADOLESCENT; ADULT; AGED; ANTICOAGULATION; ARTICLE; BLEEDING; BLOOD CELL COUNT; CLINICAL ASSESSMENT; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; FEMALE; HEALTH SURVEY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCORING SYSTEM; THAILAND; THROMBOCYTE COUNT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CROSS-SECTIONAL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROTEIN C; PROTEIN S; QUESTIONNAIRES; RISK FACTORS; SEX FACTORS; THAILAND; VON WILLEBRAND FACTOR; YOUNG ADULT;

EID: 84860337244     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2011.02678.x     Document Type: Article

References (25)

1. Sadler JE. Low von Willebrand factor: sometimes a risk factor and sometimes a disease. Hematology Am Soc Hematol Educ Program 2009; 106-12.
2. Gudmundsdottir BR, Marder VJ, Onundarson PT. Risk of excessive bleeding associated with marginally low von Willebrand factor and mild platelet dysfunction. J Thromb Haemost 2007; 5: 274-81.
3. Lethagen S, Hillarp A, Ekholm C, Mattson E, Halldén C, Friberg B. Distribution of von Willebrand factor levels in young women with and without bleeding symptoms: influence of ABO blood group and promoter haplotypes. Thromb Haemost 2008; 99: 1013-8.
4. Kunicki TJ, Federici AB, Salomon DR et al. An association of candidate gene haplotypes and bleeding severity in von Willebrand disease (VWD) type 1 pedigrees. Blood 2004; 104: 2359-67.
5. Brouwer JL, Veeger NJ, Kluin-Nelemans HC, van der Meer J. The pathogenesis of venous thromboembolism: evidence for multiple interrelated causes. Ann Intern Med 2006; 145: 807-15.
6. Martinelli I. von Willebrand factor and factor VIII as risk factors for arterial and venous thrombosis. Semin Hematol 2005; 42: 49-55.
7. Abraham E, Laterre PF, Garg R et al. Administration of Drotrecogin Alfa (Activated) in Early Stage Severe Sepsis (ADDRESS) Study Group. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 2005; 353: 1332-41.
8. Tripodi A, Mannucci PM. Abnormalities of hemostasis in chronic liver disease: reappraisal of their clinical significance and need for clinical and laboratory research. J Hepatol 2007; 46: 727-33.
9. Tosetto A, Rodeghiero F, Castaman G et al. A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD). J Thromb Haemost 2006; 4: 766-73.
10. Bowman M, Mundell G, Grabell J et al. Generation and validation of the Condensed MCMDM-1VWD Bleeding Questionnaire for von Willebrand disease. J Thromb Haemost 2008; 6: 2062-6.
11. Angchaisuksiri P, Atichartakarn V, Aryurachai K et al. Risk factors of venous thromboembolism in thai patients. Int J Hematol 2007; 86: 397-402.
12. Jespersen J, Bertina RM, Haverkate F, eds. Laboratory Techniques in Thrombosis - A Manual. Norwell, Kluwer Academic Publishers, 1999.
13. Rojnuckarin P, Akkawat B, Intragumtornchai T. von Willebrand factor (vWF) antigen levels and function in healthy Thais. Southeast Asian J Trop Med Public Health 2005; 36: 1292-7.
14. Akkawat B, Rojnuckarin P. Protein S deficiency is common in a healthy Thai population. J Med Assoc Thai 2005; 88: S249-54.
15. Hackeng TM, Seré KM, Tans G, Rosing J. Protein S stimulates inhibition of the tissue factor pathway by tissue factor pathway inhibitor. Proc Natl Acad Sci U S A 2006; 103: 3106-11.
16. Kottke-Marchant K, Comp P. Laboratory issues in diagnosing abnormalities of protein C, thrombomodulin, and endothelial cell protein C receptor. Arch Pathol Lab Med 2002; 126: 1337-48.
17. Viganò S, Mannucci PM, D'Angelo A et al. Protein C antigen is not an acute phase reactant and is often high in ischemic heart disease and diabetes. Thromb Haemost 1984; 52: 263-6.
18. Meade TW, Stirling Y, Wilkes H, Mannucci PM. Effects of oral contraceptives and obesity on protein C antigen. Thromb Haemost 1985; 53: 198-9.
19. Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation 2005; 111: 1448-54.
20. Janson PA, Jubelirer SJ, Weinstein MJ, Deykin D. Treatment of the bleeding tendency in uremia with cryoprecipitate. N Engl J Med 1980; 303: 1318-22.
21. Mannucci PM, Remuzzi G, Pusineri F et al. Deamino-8-D-arginine vasopressin shortens the bleeding time in uremia. N Engl J Med 1983; 308: 8-12.
22. Livio M, Mannucci PM, Viganò G et al. Conjugated estrogens for the management of bleeding associated with renal failure. N Engl J Med 1986; 315: 731-5.
23. Escuriola Ettingshausen C, Halimeh S, Kurnik K et al. Symptomatic onset of severe hemophilia A in childhood is dependent on the presence of prothrombotic risk factors. Thromb Haemost 2001; 85: 218-20.
24. Dargaud Y, Meunier S, Negrier C. Haemophilia and thrombophilia: an unexpected association! Haemophilia 2004; 10: 319-26.
25. Franchini M, Montagnana M, Targher G et al. Interpatient phenotypic inconsistency in severe congenital hemophilia: a systematic review of the role of inherited thrombophilia. Semin Thromb Hemost 2009; 35: 307-12.